治疗结核病的神奇药物:贝达喹啉

R. Kandasamy, S. Venkataramanan
{"title":"治疗结核病的神奇药物:贝达喹啉","authors":"R. Kandasamy, S. Venkataramanan","doi":"10.5005/JP-JOURNALS-10084-12174","DOIUrl":null,"url":null,"abstract":"A new tuberculosis (TB) medication includes the active ingredient bedaquiline. Sirturo is a brand name for a drug that belongs to the diarylquinoline class of drugs. Bedaquiline is a diarylquinoline antimycobacterial drug that works by blocking an enzyme within the bacteria that cause TB. It prevents the proton pump of mycobacterial adenosine 5 ′ -triphosphate (ATP) synthase. Bedaquiline is metabolized in hepatic form and eliminated in the feces. Bedaquiline is effective and safe in treating multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) patients. This drug treatment regimen was well supported and tended to a good result in this clinically relevant patient associated with MDR-TB.","PeriodicalId":107391,"journal":{"name":"Pondicherry Journal of Nursing","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Miracle Drug for Tuberculosis: Bedaquiline\",\"authors\":\"R. Kandasamy, S. Venkataramanan\",\"doi\":\"10.5005/JP-JOURNALS-10084-12174\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A new tuberculosis (TB) medication includes the active ingredient bedaquiline. Sirturo is a brand name for a drug that belongs to the diarylquinoline class of drugs. Bedaquiline is a diarylquinoline antimycobacterial drug that works by blocking an enzyme within the bacteria that cause TB. It prevents the proton pump of mycobacterial adenosine 5 ′ -triphosphate (ATP) synthase. Bedaquiline is metabolized in hepatic form and eliminated in the feces. Bedaquiline is effective and safe in treating multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) patients. This drug treatment regimen was well supported and tended to a good result in this clinically relevant patient associated with MDR-TB.\",\"PeriodicalId\":107391,\"journal\":{\"name\":\"Pondicherry Journal of Nursing\",\"volume\":\"2 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pondicherry Journal of Nursing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5005/JP-JOURNALS-10084-12174\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pondicherry Journal of Nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/JP-JOURNALS-10084-12174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

一种新的结核病药物包括有效成分贝达喹啉。Sirturo是一种药物的品牌名称,属于二芳基喹啉类药物。贝达喹啉是一种二芳基喹啉抗细菌药物,通过阻断引起结核病的细菌内的一种酶起作用。它可以阻止分枝杆菌5 ' -三磷酸腺苷(ATP)合成酶的质子泵。贝达喹啉以肝脏形式代谢,并随粪便排出。贝达喹啉对治疗耐多药结核病(MDR-TB)和广泛耐药结核病(XDR-TB)患者有效且安全。这种药物治疗方案得到了很好的支持,并倾向于在与耐多药结核病相关的临床相关患者中取得良好的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A Miracle Drug for Tuberculosis: Bedaquiline
A new tuberculosis (TB) medication includes the active ingredient bedaquiline. Sirturo is a brand name for a drug that belongs to the diarylquinoline class of drugs. Bedaquiline is a diarylquinoline antimycobacterial drug that works by blocking an enzyme within the bacteria that cause TB. It prevents the proton pump of mycobacterial adenosine 5 ′ -triphosphate (ATP) synthase. Bedaquiline is metabolized in hepatic form and eliminated in the feces. Bedaquiline is effective and safe in treating multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) patients. This drug treatment regimen was well supported and tended to a good result in this clinically relevant patient associated with MDR-TB.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A Descriptive Study to Determine the Quality of Life among Transgenders Residing at Puducherry Building Emotional Resilience in Nursing Students: Overview World Osteoporosis Day 2023: “Step Up for Bone Health–Build Better Bones” To Assess the Utility of BASNEF Model on the Quality of Life among Perimenopausal Women in the Rural Community Setting Asherson\'s Disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1